In summary, our data suggested that β-Asarone could be a potential drug for the treatment of lymphomas by increasing doxorubicin sensitivity via inhibiting NF-κB signaling and by targeting stem-like population to overcome drug resistance via reducing Bmi1 stability (Fig. 7). This evidence concerns the gene BMI1 and lymphoma.